Faculty

In The Crossfire 2014: Faculty

Omar Khan, MD, FRCP, Moderator

Omar Khan, MD, FRCP, Moderator

Disclosure
Speaker’s Bureau/Research Grant/Consultant: Teva CNS, Novartis
Research Grant/Consultant: Biogen Idec, Genzyme
Research Support: Acorda Therapeutics, Sanofi

Biography

Chairman and Professor of Neurology,
Neurologist-in-Chief, Detroit Medical Center;
Director, Wayne State University Multiple Sclerosis Center &
The Sastry Foundation Advanced Imaging Laboratory;
Wayne State University School of Medicine

Detroit, MI

Dr. Omar Khan joined the Department of Neurology, Wayne State University School of Medicine in 1998. He was previously a member of the Department of Neurology, University of Maryland School of Medicine and the Veterans Affairs Medical Center, Baltimore. Dr. Khan serves on numerous Advisory and Research Committees including the National Multiple Sclerosis Society (USA), European Charcot Foundation for Multiple Sclerosis Research, The National Institutes of Health, Canadian Health Research Institute, Multiple Sclerosis Society of Canada, and the U.S. Food & Drug Administration. Dr. Khan is a member of the American Academy of Neurology and an elected member of the American Neurological Association.

Dr. Khan’s research and clinical interests include Multiple Sclerosis and related diseases including Neuromyelitis Optica (NMO) and Transverse Myelitis; high-risk MS pregnancy cases; neurologic complications of lupus, sarcoidosis, and vasculitis. Dr. Khan also specializes in the treatment of aggressive forms of multiple sclerosis with chemotherapy and other emerging treatments. Dr. Khan established the largest African-American Multiple Sclerosis Clinic in the U.S. where he is investigating the role of genetics and treatment of African-American MS patients. Dr. Khan also has keen interest in pediatric MS. Over the years, his research has been funded by the National Institutes of Health, the National Multiple Sclerosis Society, Department of Veterans Affairs, and the pharmaceutical industry.

Edward J. Fox, MD, PhD, Panelist

Edward J. Fox, MD, PhD

Disclosure
Consultant/Speaker’s Bureau: Biogen Idec, EMD Serono, Genzyme, Opexa Therapeutics,
Pfizer, Teva CNS

Biography

Director, Multiple Sclerosis Clinic of Central Texas
Clinical Assistant Professor at the University of Texas Medical Branch,

Round Rock, TX

Dr. Edward Fox is a Diplomate of the American Academy of Psychiatry and Neurology, and is board certified in Neurology. He completed combined MD/PhD degrees through the Medical Scientist Training Program at Baylor College of Medicine in Houston, with a PhD focus on Immunology. Dr. Fox also completed his residency in Neurology at Baylor, where he was appointed Chief Administrative Resident and selected Outstanding Academic Resident in Neurology.

Dr. Fox is renowned in the area of multiple sclerosis, and in 2003 was named to the Volunteer Hall of Fame by the Lone Star Chapter of the National Multiple Sclerosis Society, an organization for which he serves on the Clinical Advisory Committee. In 2004, Dr. Fox was appointed Clinical Assistant Professor at the University of Texas Medical Branch. In addition to treating patients, Dr. Fox conducts extensive research in the field of multiple sclerosis. His works have been published in numerous medical journals such as the Journal of Immunology and Neurology. Dr. Fox’s research is directed at various facets of multiple sclerosis, including the study of pharmaceutical agents and their mechanism of action, as well as methods of managing the disease as it worsens. Dr. Fox holds a bachelor’s degree in Biology from Washington University in St. Louis, Missouri. While pursuing his undergraduate degree, he was involved with immunological research at Washington University and at M.D. Anderson Hospital and
Tumor Institute.

Bruce Cree, MD, PhD, MCR, Panelist

Bruce Cree, MD, PhD, MCR

Disclosure
Consultant: Biogen Idec; EMD Serono; Sanofi /Genzyme, Teva CNS, Medimmune; Novartis
Research Support (including clinical trials): Novartis; Roche, Genentech; Acorda Therapeutics; Receptos

Biography

Associate Professor of Neurology, UCSF School of Medicine
Clinical Research Director, UCSF MS Center

San Francisco, CA

Dr. Bruce Cree received his Sc.B. in Neuroscience and A.B. in psychology in 1987 from Brown University. Dr. Cree completed his PhD in Biochemistry and his MD in 1997 at UCSF. His neurology residency training was completed at Columbia University in 2001. He returned to UCSF for his multiple sclerosis fellowship where he received a Masters in Clinical Research. He was a National Multiple Sclerosis Society Sylvia Lawry fellow and received a K-23 career development award from of the National Institute of Health.

Dr. Cree currently serves as the Clinical Research Director at the UCSF MS Center. He divides his time between patient care, clinical research and teaching. His research focuses on the genetic epidemiology of multiple sclerosis, the immunology of neuromyelitis optica and developing novel therapies for multiple sclerosis and neuromyelitis optica through clinical trials.

Fred D Lublin, MD

Fred D Lublin, MD

Disclosure
Research Support: Acorda Therapeutics, Inc.; Biogen Idec; Novartis Pharmaceuticals Corp; Teva CNS; Genzyme; Sanofi; Celgene; NIH; NMSS
Current Financial Interests/Stock Ownership: Cognition Pharmaceuticals, Inc.

Biography

Saunders Family Professor of Neurology,
Director, the Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center

New York, NY

Dr. Fred Lublin is an internationally renowned neuroimmunologist with a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis. He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS.

Dr. Lublin was chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society’s Research Programs Advisory Committee. He is a member of the National MS Society National Board of Directors and their medical advisory board, and also is Chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee. He is also a member of the executive committee of the International Medical & Scientific Board of the Multiple Sclerosis International Federation.

Dr. Lublin and his colleagues at the National MS Society have re-defined the clinical course definitions of MS using data from a survey of the international MS community. He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr. Lublin is also a member of the international panel that periodically redefines the diagnostic criteria for MS.

Dr. Lublin has published numerous scientific articles and belongs to many professional societies and advisory boards. Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He is the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis.